Background {#Sec1}
==========

Connective tissue diseases comprise over 100 disorders that are characterized by chronic inflammation and impaired quality of life. During the last two decades major therapeutic advances have been accomplished in this field, however patients with such disorders are clinically complex and in addition to the disease burden itself, the interplay between the disease activity and associated conditions may lead to increased morbidity and mortality. These comorbid conditions can preexist or arise as a result of the disease itself, and the concomitant treatments and continuous vigilance for prompt diagnosis and treatment is warranted.

Systemic sclerosis (SSc) is a rare disease that significantly affects quality of life and is characterized with one of the highest mortality rates among the various autoimmune diseases with an estimated standardized mortality ratio between 2.5 and 4.0 \[[@CR1], [@CR2]\]. Despite the impact of the disease in survival and quality of life, data on the epidemiology and clinical expression of comorbidities in SSc so far are limited. Conversely the interactions between disease-related inflammatory processes and development of several comorbidities has been thoroughly investigated in rheumatoid arthritis (RA) \[[@CR3]\]. This is particularly the case for cardiovascular disease (CVD) \[[@CR4]\], where RA is considered to be an independent predictor of the development of CVD with comparable CV risk to diabetes mellitus (DM) \[[@CR5], [@CR6]\].

To date there are no comparative studies examining the prevalence of the most relevant comorbidities in SSc versus RA. Our objective was to compare the prevalence of comorbidities in two multicenter, matched-cohorts of patients with SSc and RA.

Methods {#Sec2}
=======

Study population {#Sec3}
----------------

In the current study we included patients with SSc and RA from six academic Rheumatology Departments across Greece with substantial experience in the management of connective tissue diseases. Patients with SSc were recruited consecutively between 2016 and 2017 and were matched 1:1 for age and gender with RA patients, all meeting the 1980 American College of Rheumatology (ACR) criteria \[[@CR7]\] and the 1987 ACR criteria \[[@CR8]\], respectively. RA patients were derived from the working cohort of an ongoing, multicenter prospective RA study involving 2491 patients (from the RA Study Group of the Greek Rheumatology Society) \[[@CR9]\]. Ethical approval was provided by the local institutional boards of participating centers and informed consent was provided by all patients before their inclusion in the study. In both cohorts, information about cumulative comorbidity conditions was collected from the medical history records of the patients.

The comorbidities evaluated were dyslipidemia, DM, arterial hypertension, smoking, coronary artery disease (CAD), stroke, chronic obstructive pulmonary disease, osteoporosis, neoplasms and depression. Dyslipidemia was defined by total cholesterol of 240 mg/dl and/or low-density lipoprotein of 130 mg/dl and/or triglycerides of 160 mg/dl and/or intake of lipid-lowering drugs. A diagnosis of DM was based on the requirement for antidiabetic drugs. Arterial hypertension was defined by systolic blood pressure \> 140 mmHg and/or diastolic blood pressure \> 90 mmHg on two measurements or when antihypertensive treatment was administered after the diagnosis of hypertension was established. Patients receiving antihypertensive agents in the context of vasodilatory therapy not fulfilling criteria for hypertension were excluded from the analysis. Smoking was categorized as current smoker, ex-smoker or never smoked. CAD was defined by the presence of at least one of the following: myocardial infarction or angina pectoris based on clinical diagnosis and ischemic changes in the electrocardiogram and/or specific changes in cardiac enzymes and/or typical findings on coronary angiography. Stroke was defined by the presence of ischemic or hemorrhagic stroke based on clinical manifestations and/or supported by an imaging study. Chronic obstructive pulmonary disease (COPD) was defined by the administration of therapy for chronic bronchitis or emphysema. Osteoporosis was defined by [bone density](https://en.wikipedia.org/wiki/Bone_density) 2.5 standard deviations below that of a young adult measured by [dual-energy x-ray absorptiometry](https://en.wikipedia.org/wiki/Dual-energy_X-ray_absorptiometry). Νeoplasia diagnosis was based on patients' medical records according to pathologic tissue biopsy of the affected organ. The diagnosis of depression was based on antidepressant therapy administered after psychiatric evaluation.

Statistical analysis {#Sec4}
--------------------

Values related to categorical variables are expressed as percentages. Continuous variables are expressed as means ± SD. Data were compared using the chi-square test for categorical data and the Kruskal-Wallis test for continuous data. Association was tested using binomial logistic regression. Results are expressed as odds ratios (ORs). All analyses were carried out using the software Stata 13.1 and SPSS 21.

Results {#Sec5}
=======

Patient demographics {#Sec6}
--------------------

A total of 408 patients with SSc were included, 55% had the diffuse subtype, 89% were women, mean age at inclusion was 58.4 ± 14.5 years and patients were matched 1:1 for age and gender to 408 patients with RA. As shown in Table [1](#Tab1){ref-type="table"}, disease duration was comparable between patients with SSc and patients with RA (10.1 ± 7.7 years vs 9.2 ± 7.8 years, respectively, *p* not significant (NS)), while no significant differences were observed in smoking or current treatment with corticosteroids (treatment duration and mean dose). On the other hand, body mass index (BMI) was significant higher in patients with RA (26.5 ± 4.86 vs 24.2 ± 3.61, *p* = 0.001). In Table [1](#Tab1){ref-type="table"}, the characteristics of the limited and diffuse SSc subgroups and those of their matched patients with RA are also shown.Table 1Demographic characteristics of systemic sclerosis (SSc) and rheumatoid arthritis (RA) matched cohortsSScRALimited SScRA matched to limited SScDiffuse SScRA matched to diffuse SScNumber of patients408408182182226226Female, *n* (%)364 (89%)364 (89%)169 (93)169 (93)195 (86)195 (86)Age at inclusion (years)58.4 ± 13.557.5 ± 13.458.3 ± 12.657.4 ± 12.558.7 ± 14.257.9 ± 13.9Disease duration (years)10.1 ± 7.89.2 ± 7.78.85 ± 8.798.3 ± 7.3910.7 ± 8.410.2 ± 7.9Smoking, *n* (%)104 (25.4%)128 (31.3%)54 (29.7)59 (32.4)50 (22.1)69 (30.6)Body mass index24.2 ± 3.626.5 ± 4.9 ^\*^24.4 ± 4.026.8 ± 4.8 ^\*^24.1 ± 3.426.1 ± 4.7 ^\*^Current corticosteroid treatment196 (48%)185 (45%)78 (43.1)84 (46.7)118 (48.7)101 (44.7) Duration (months)14.6 ± 21.615.5 ± 2614.1 ± 20.813.8 ± 36.515.2 ± 21.715.9 ± 36.9 Μean daily dose (mg)2.8 ± 1.33.2 ± 1.52.3 ± 2.12.9 ± 3.23.1 ± 2.43.3 ± 2.6Data are shown as mean ± 1 standard deviation^\*^*p* \< 0.05

Comorbidities {#Sec7}
-------------

A comparative analysis of the prevalence of comorbidities between the two cohorts is shown in Table [2](#Tab2){ref-type="table"}. Dyslipidemia (17.7% vs 30.2%, *p* = 0.001), and DM (5.6% vs 11.8%, *p* = 0.007) were less prevalent in SSc and RA, respectively, and the respective ORs were 0.5 (95% CI 0.36--0.69) and 0.45 (95% CI 0.27--0.75). On the contrary no differences were noted for the prevalence of arterial hypertension (31.8% vs 30.6%, respectively, *p* = 0.742). Despite the higher BMI and almost double the prevalence of dyslipidemia and DM in RA, no remarkable differences in coronary events (2.7% vs. 3.7%, *p* = 0.445; OR 0.73 (95% CI 0.33--1.60)) or stroke (1.9% vs 3.4%, *p* = 0.195; OR 0.56 (95% CI 0.23--1.35)) were noted between the two groups, although a trend for lower prevalence of ischemic stroke in patients with SSc than in patients with RA was observed (1.2% vs 2.9%, *p* = 0.085; OR 0.40 (95% CI 0.14--1.17)). Additionally, when we adjusted the analysis for corticosteroid treatment, hypertension and dyslipidemia, no relevant changes in the ORs were observed (Table [2](#Tab2){ref-type="table"}).Table 2Prevalence of comorbidities in systemic sclerosis (SSc) and rheumatoid arthritis (RA) matched cohortsComorbiditySScRACrude ORAdjusted ORDiabetes mellitus23 (5.6)48 (11.8)0.45 (0.27--0.75)--Dyslipidemia72 (17.7)123 (30.2)0.50 (0.36--0.69)--Arterial hypertension131 (32.1)125 (30.6)1.07 (0.80--1.44)--Coronary event11 (2.7)15 (3.7)0.73 (0.33--1.60)0.74 (0.34--1.62)^\*^Stroke8 (1.9)14 (3.4)0.56 (0.23--1.35)0.55 (0.21--1.32)^\*^Ischemic stroke5 (1.2)12 (2.9)0.40 (0.14--1.17)0.39 (0.14--1.15)Hemorrhagic stroke3 (0.7)2 (0.5)1.5 (0.25--9.04)1.48 (0.23--8.96)Neoplasia17 (4.2)19 (4.7)0.89 (0.46--1.74)--Chronic obstructive pulmonary disease21 (5.2)15 (3.7)1.42 (0.72--2.80)1.46 (0.74--2.90)^\*\*^Osteoporosis98 (24.0)92 (22.6)1.09 (0.79--1.50)1.08 (0.78--1.49)^\*\*\*^Depression90 (22.1)49 (12)2.07 (1.42--3.03)--All data are shown as number (percentage)*OR* odds ratio^\*^Adjusted for smoking, corticosteroid treatment, arterial hypertension, dyslipidemia^\*\*^Adjusted for smoking^\*\*\*^Adjusted for corticosteroid treatment

The overall prevalence of malignancies did not differ between SSc and RA (4.2% vs 4.7%, *p* = 0.733; OR 0.89 (95% CI 0.46--1.74)). However, there were differences in the type of neoplasms observed in the two cohorts. In particular, in the SSc cohort the most frequent type was lung cancer (7/17, 41%), while patients with RA developed mainly hematologic malignancies (7/19, 36%) and breast cancer (7/19, 36%).

Among the other comorbidities analyzed, the prevalence of chronic obstructive pulmonary disease (5.2% vs 3.7%, respectively, *p* = 0.326), osteoporosis or osteoporotic fractures was similar between the two groups (24% vs 22%, *p* = 0.619; OR 1.08 (\[95% CI 0.78--1.49) and 6.1% vs 6.7%, *p* = 0.665; OR 1.13 (95% CI 0.64--2.0), respectively). However, depression (defined by the use of antidepressants) was almost twice as frequent in SSc compared to patients with RA (22% vs 12%, *p* = 0.001; OR 2.07 (95% CI 1.42--3.03), respectively).

In addition, sub-analysis between patients with limited (*n* = 182) or diffuse SSc (*n* = 226) and matched patients with RA was performed in order to examine the impact of SSc subtype on the prevalence of comorbidities. As shown in Table [3](#Tab3){ref-type="table"}, with the exception of depression, no other differences were noted compared to the primary analysis. Dyslipidemia and DM were confirmed to be significantly less prevalent both in limited or diffuse SSc compared to RA, while no differences were noted in the prevalence of arterial hypertension, coronary events, stroke, malignancies, chronic obstructive pulmonary disease or osteoporosis. On the contrary, the sub-analysis revealed that depression was significantly more frequent in the diffuse SSc subgroup compared to matched patients with RA (27.2% vs 11.9%, *p* = 0.001; OR 2.753 (95% CI 1.675--4.523)), while it was comparable between patients with limited SSc and patients with RA (14.8% vs 12.1%, *p* = 0,455; OR 1.259 (CI 95% 0.688--2.304)).Table 3Prevalence of comorbidities in limited or diffuse systemic sclerosis (SSc) and rheumatoid arthritis (RA) matched controlsComorbidityLimited SSc\
*n* = 182RA\
*n* = 182ORDiffuse SSc\
*n* = 226RA\
*n* = 226ORDiabetes mellitus12 (6.6)23 (12.6)0.485 (0.234--1.007)11 (4.8)25 (11.1)0.408 (0.195--0850)Dyslipidemia34 (18.7)56 (30.8)0.513 (0.315--0.836)38 (16.7)67 (29.6)0.475 (0.303--0.745)Arterial hypertension56 (30.8)54 (29.7)1.04 (0.668--1.635)75 (33.2)71 (31.4)1.084 (0.731--1.609)Coronary event4 (2.2)6 (3.3)0.655 (0.182--2.363)7 (3.1)9 (4.0)0.764 (0.279--2.087)Stroke5 (2.7)6 (3.3)0.824 (0.247--2.749)3 (1.3)8 (3.5)0.363 (0.095--1.387)Ischemic3 (1.6)5 (2.7)0.590 (0.139--2.506)2 (0.9)7 (3.1)0.277 (0.057--1.347)Hemorrhagic2 (1.1)1 (0.5)2.00 (0.18--22.252)1 (0.4)1 (0.4)0.991 (0.062--15.944)Neoplasia7 (3.8)8 (4.4)0.865 (0.307--2.437)10 (4.4)11 (4.9)0.897 (0.373--2.155)Chronic obstructive pulmonary disease8 (4.4)6 (3.3)1.341 (0.456--3.945)13 (5.7)9 (4.0)1.758 (0.610--3.482)Osteoporosis41 (22.4)39 (21.4)1.09 (0.79--1.50)57 (25)52 (23)1.115 (0.725--1.716)Depression27 (14.8)22 (12.1)1.259 (0.688--2.304)63 (27.6)27 (11.9)2.814 (1.714--4.620)

Discussion {#Sec8}
==========

It is well-established that comorbidities significantly contribute to the morbidity and mortality of rheumatic diseases; however, available data on their relative frequency and impact are limited \[[@CR10]--[@CR13]\]. Herein, we compared the prevalence of the most frequent comorbidities in two well-matched cohorts of patients with SSc and RA; to our knowledge this is the first such comparative study.

The most interesting result of the present study is that no significant differences in the occurrence of cardiovascular (CV) events were noted between patients with SSc and patients with RA, despite the fact that the prevalence of dyslipidemia and diabetes mellitus, two major risk factors for the development of CVD, was almost double in RA compared to SSc. Previous studies in patients with SSc have demonstrated an increased burden of CVD compared to the general population \[[@CR14]--[@CR16]\] despite a similar \[[@CR17], [@CR18]\] or even lower \[[@CR15], [@CR19]\] prevalence of traditional CV risk factors. It seems therefore that CVD in SSc is complex and multifactorial and except for atherosclerosis and chronic inflammation, other disease-specific mechanisms like microangiopathy and vasospasm may be key in the development of CVD in patients with SSc \[[@CR20]--[@CR25]\].

Microvasculopathy is well-documented in SSc and although not yet clearly elucidated through which mechanisms, it seems to contribute to the development of macrovascular disease, probably through pathologic processes like endothelial dysfunction, endothelial cell activation and impaired vascular remodeling. This hypothesis is supported by the reports from some studies that renal crisis \[[@CR19]\] and pulmonary arterial hypertension (PAH) \[[@CR15], [@CR26]\], the two major clinical characteristics of microvasculopathy, are independent predictors of CVD. Moreover, the fact that PAH is in general more prevalent in SSc compared to RA \[[@CR27]\] may reflect an increased burden of endothelial dysfunction in patients with SSc, enhancing the aforementioned hypothesis and potentially explaining the similar CV risk in the two diseases despite the lower prevalence of other common CVD risk factors in Patients with SSc. Finally, coronary vasospasm or myocardial Raynaud's phenomenom, as it is usually called, contributes to a degree to the pathogenesis of CVD in SSc, most likely through the development of focal areas of myocardial fibrosis and contraction-band necrosis as a result of reperfusion injury \[[@CR28]\].

Another interesting finding of our study was the higher prevalence of depression requiring treatment in patients suffering from diffuse SSc compared to RA. Several studies have investigated the prevalence of depression in rheumatic diseases with significant variability in the reported results, probably due to different criteria used to define depression. In a recent Canadian study of 345 patients the estimated depression rate in SSc was \~ 23% \[[@CR29]\], while in a systematic review of eight studies the prevalence ranged from 36 to 65% \[[@CR30]\]. In our study the respective rate based on the use of antidepressants was 22%.

On the other hand, in a meta-analysis of 72 studies in patients with RA, the prevalence of depression disorders ranged between 16.8% and 38.8% (depending on which assessment measures were applied) \[[@CR31]\], while in our study it was somewhat lower (12%). The results of our study showed that SSc and especially the diffuse subtype exerts a greater psychosocial burden than RA, but these results are only indicative and properly conducted studies with standardized criteria for diagnosis of depression are needed in order to make secure conclusions.

There were no significant differences between the two groups in the other comorbidities that were analyzed. Of note, although the overall prevalence of neoplasms was comparable between the two groups, the most common neoplasm observed in patients with SSc was lung cancer, whereas patients with RA more often developed hematologic malignancies and breast cancer. The increased relative risk of development of lung cancer in SSc is well-established as shown in two meta-analyses \[[@CR32], [@CR33]\] and reflects the direct causal association between SSc and lung cancer due to the increased prevalence of interstitial lung disease and the presence of chronic lung inflammation. On the other hand, the increased prevalence of breast cancer in our RA cohort is in opposition to the results of other meta-analyses, which indicate reduced risk of breast cancer in RA \[[@CR34], [@CR35]\], but this discrepancy might be explained by the inevitable over representation of female gender in our RA cohort.

Our study has certain limitations that should be addressed. First, the RA cohort is not a random population sample and as mentioned previously is characterized by over representation of female patients, and the prevalence noted might be different from that in other RA populations. Another important limitation is the lack of information on the concomitant immunosuppressive therapy that patients had received and as a consequence the effect of such treatments in the development of various comorbidities was not analyzed. Also we did not use any standardized questionnaire to measure depression and the diagnosis of depression was based only on the administration of antidepressant treatment after psychiatric evaluation.

Conclusions {#Sec9}
===========

To conclude, this is the first study in the literature directly assessing the prevalence of common comorbidities in SSc versus RA. These results indicate that SSc has comparable cardiovascular risk to RA but poses a greater negative impact on quality of life, as more patients with SSc develop depression. Further studies that will evaluate the epidemiology and pathophysiology of various comorbidities in different rheumatic diseases will provide additional information on the disease-specific risk factors and underlying mechanisms so as to define optimal preventive and therapeutic strategies.
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